about pic
HomeSite MapContact Us
About Us: Team
about
Benjamin Soffer
ITTN - Co. Chairman of the Board.
Benjamin Soffer joined the Technion as CEO of T3 - Technion Technology Transfer office in 2005. As part of his duties at T3, Mr. Soffer is responsible for the establishment of startup companies and the commercialization of technologies arising from the Technion research. His Experience spans over 20 years in the areas of investment, industry and government in Israel, Europe, and the United States. In addition, Mr. Soffer serves as CEO of AMIT, a Technion hub for biomedical innovation; Chairman of T-Factor, the Technion engineering accelerator and , and Chairman of the ITTN – The Israeli Technology Transfer Organization. In addition Mr. Soffer serves on the boards of directors of numerous high growth companies. Prior to his position at the Technion, Mr. Soffer served as managing director of TopNotch Capital - and was as an investment advisor at Highbridge Capital. Between 1999 and 2003 he served as Israel's Economic attaché in Boston. There, Mr. Soffer was responsible for enhancing economic and business relations between Israel and the US Northeast region through private equity investments, joint ventures and trade. Prior to his tenure in Boston, Mr. Soffer served as special advisor to Dr. Orna Berry, Israel's chief scientist at the Ministry of Industry and Trade, where played a pivotal role in the initiation and implementation of innovative R&D programs. A certified lawyer in Israel and in the state of New York, Mr. Soffer has interned at Israel's Supreme Court and studied law at Tel Aviv University and at Ludwig Maximilian University in Munich. Additionally, he studied economics and business administration at Bar - Ilan University.
Orit Shaked
ITTN - Director
Dr Shaked is the CEO of Biorap Technologies – the technology transfer unit of the Rappaport Family Institute for Research in the Medical Sciences. Dr Shaked is responsible for providing Rappaport Institute scientists with assistance in business development, strategic alliance development, identification of investors, establishment of startups, and other areas associated with commercialization of medical technologies. In addition, Biorap Technologies is responsible for managing the Genomic Core Facility which provides top tier genomic technologies to universities, hospitals and biopharma companies.
Until 2010 Dr. Orit Shaked was the Chief Technology Officer and Business Development at Meytav Technological Incubator. Prior to joining Meytav, Dr. Shaked served as the Director of Product ID and Portfolio management at Teva Pharmaceuticals, specializing in Biosimilar and Hospital franchises (Autoimmune diseases, Oncology, Endocrinology and Wound healing). She was responsible for project analysis, market opportunities evaluation and launch of the first Bio-similar product. Dr. Shaked was also the Managing Director of UBT Medical. She also held several research and development and business development positions in bio start-ups. Dr. Shaked is a Director of ITTN (Israel Tech Transfer Organization). And Turboseal Ltd. She holds a Ph.D. in Medical Sciences and an M.B.A. from the Technion – Israel institute of Technology.
Gil Granot-Mayer
ITTN – Director
Gil Granot-Mayer holds an MBA degree from the Leon Recanati Graduate School of Business Administration and an LL.B. degree from Tel-Aviv University. Mr. Granot-Mayer was appointed as Yeda’s C.E.O in 2016 after having served as Deputy C.E.O and General Counsel of Yeda for 10 years. Prior to joining Yeda, Mr. Granot-Mayer worked in prominent law firms both as a commercial lawyer and as a litigator specializing in Intellectual Property, Cyberspace Law, E-commerce and Banking.
Mr. Granot-Mayer is a frequent speaker in various forums covering issues related to Intellectual Property, licensing and technology transfer.
Gil served in the Israeli Navy as a submarine crewmember during his extended military service.
Gil is married and has three children.
ITTN - Israel Tech Transfer Organization